PL
PL

Change to the Agenda of the Annual General Meeting of Diagnostyka S.A. Convened for 25 May 2026

Current reports : Current Report No. 7/2026

Date : 07.05.2026

Hour : 17:13

Date: 7 May 2026

Subject: Change to the agenda of the Annual General Meeting of Diagnostyka S.A. convened for 25 May 2026

Legal basis: Article 56(1)(2) of the Act on Public Offering – current and periodic information

Text of the report:

The Management Board of Diagnostyka S.A. (the “Company”) announces a change to the agenda of the Annual General Meeting of Diagnostyka S.A. convened for 25 May 2026, made at the request of Shareholders representing at least one-twentieth of the share capital, submitted on 3 May 2026.

The change to the agenda consists in adding the following items:

“27. Adoption of a resolution concerning the remuneration of the Supervisory Board (on amending Resolution No. 6 of the Extraordinary General Meeting of Shareholders of 28 April 2025 concerning the remuneration of the Supervisory Board)” and

“28. Giving an opinion on the remuneration report referred to in Article 90g of the Act of 29 July 2005 on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organised Trading, and on Public Companies, for 2025.”

The new agenda is as follows:

  1. Opening of the Annual General Meeting.
  2. Election of the Chairperson of the Annual General Meeting.
  3. Confirmation that the Annual General Meeting has been duly convened and is capable of adopting binding resolutions.
  4. Adoption of the agenda.
  5. Review of the reports of the Company’s governing bodies, the Company’s financial statements and the consolidated financial statements for 2025.
  6. Adoption of a resolution on the approval of the Company’s financial statements for 2025.
  7. Adoption of a resolution on the approval of the consolidated financial statements of the Diagnostyka Capital Group for 2025.
  8. Adoption of a resolution on the approval of the Management Board’s Report on the Operations of Diagnostyka S.A. and the Diagnostyka Capital Group for the 2025 financial year (including the Management Board’s report on the operations of the parent company – Diagnostyka S.A. – and the sustainability reporting of the Diagnostyka Capital Group for 2025).
  9. Adoption of a resolution on the distribution of the Company’s profit for 2025.
  10. Adoption of a resolution on granting discharge to Mr Jakub Swadźba, President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  11. Adoption of a resolution on granting discharge to Mr Dariusz Zowczak, Vice President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  12. Adoption of a resolution on granting discharge to Ms Marta Rogalska-Kupiec, Vice President of the Management Board, in respect of the performance of her duties for the period from 1 January to 31 December 2025.
  13. Adoption of a resolution on granting discharge to Mr Paweł Chyła, Vice President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  14. Adoption of a resolution on granting discharge to Mr Jaromir Pelczarski, Vice President of the Management Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  15. Adoption of a resolution on granting discharge to Mr Artur Olender, Chairperson of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  16. Adoption of a resolution on granting discharge to Mr Jacek Prusek, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  17. Adoption of a resolution on granting discharge to Mr Grzegorz Głownia, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  18. Adoption of a resolution on granting discharge to Mr Marcin Fryda, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 31 December 2025.
  19. Adoption of a resolution on granting discharge to Ms Aniela Hejnowska, Member of the Supervisory Board, in respect of the performance of her duties for the period from 1 January to 31 December 2025.
  20. Adoption of a resolution on granting discharge to Mr Paweł Malicki, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 28 April 2025.
  21. Adoption of a resolution on granting discharge to Mr Matthew Strassberg, Member of the Supervisory Board, in respect of the performance of his duties for the period from 1 January to 28 April 2025.
  22. Adoption of a resolution on granting discharge to Mr Paweł Leżański, Member of the Supervisory Board, in respect of the performance of his duties for the period from 28 April to 31 December 2025.
  23. Adoption of a resolution on granting discharge to Mr Piotr Solorz, Member of the Supervisory Board, in respect of the performance of his duties for the period from 28 April to 31 December 2025.
  24. Adoption of a resolution on granting discharge to Ms Patrycja Swadźba, Member of the Supervisory Board, in respect of the performance of her duties for the period from 28 April to 31 December 2025.
  25. Adoption of a resolution on the approval of the annual report of the Company’s Supervisory Board for 2025.
  26. Adoption of a resolution on the merger with the Company’s subsidiary, Laboratoria Medyczne NOVALAB sp. z o.o., with its registered office in Suwałki.
  27. Adoption of a resolution concerning the remuneration of the Supervisory Board (on amending Resolution No. 6 of the Extraordinary General Meeting of Shareholders of 28 April 2025 concerning the remuneration of the Supervisory Board).
  28. Giving an opinion on the remuneration report referred to in Article 90g of the Act of 29 July 2005 on Public Offering and Conditions Governing the Introduction of Financial Instruments to Organised Trading, and on Public Companies, for 2025.
  29. Closing of the Annual General Meeting.

Attached to this report, the Company provides the Management Board’s resolution together with the notice of the change to the agenda.

In connection with the change to the agenda introduced at the request of Shareholders, the Company additionally provides all draft resolutions of the Annual General Meeting (i.e. a consolidated text including the newly added resolutions), as well as information on draft resolutions submitted by the Shareholders. At the same time, the Company is also publishing updated forms for postal voting and voting by proxy.

The remaining documents were previously made available on the Company’s website, www.grupadiagnostyka.pl/dla-inwestorow/, in the “Periodic Reports” and “Current Reports” sections, as well as in the “General Meeting” section.

Legal basis: § 20(1)(1)–(4) of the Regulation of the Minister of Finance of 6 June 2025 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required under the laws of a state that is not a Member State.

 

For the Company:

Jakub Swadźba – President of the Management Board

Dariusz Zowczak – Vice President of the Management Board

 

Left arrow icon